1. Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia

   • David Dingli
   • Ayalew Tefferi

   OriginalPaper Pages: 69 - 74

2. The JAK2^V617F tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective

   • Martha Wadleigh
   • D. Gary Gilliland

   OriginalPaper Pages: 75 - 80

3. A refined diagnostic algorithm for polycythemia vera that incorporates mutation screening for JAK2^V617F

   • Ayalew Tefferi

   OriginalPaper Pages: 81 - 86

4. Is it justified to perform a bone marrow biopsy examination in sustained erythrocytosis?

   • Juergen Thiele
   • Hans Michael Kvasnicka

   OriginalPaper Pages: 87 - 92

5. Modern antifungal therapy for neutropenic fever

   • Melissa Corey

   OriginalPaper Pages: 95 - 100

6. Targeting the c-kit receptor in the treatment of acute myelogenous leukemia

   • Anjali S. Advani

   OriginalPaper Pages: 101 - 107

7. Chemotherapy for patients with acute myeloid leukemia in first remission

   • Kenneth Bradstock

   OriginalPaper Pages: 108 - 113

8. Clinical implications of gene expression profiling of acute myeloid leukemia

   • Kenneth I. Mills
   • Amanda F. Gilkes

   OriginalPaper Pages: 114 - 121

9. Is cytarabine required in the treatment of acute promyelocytic leukemia?

   • Lionel Adès
   • Pierre Fenaux

   OriginalPaper Pages: 122 - 125

10. Gene arrays in lymphoma: Where will they fit in?

    • Javeed Iqbal
    • Francesco d’Amore
    • Kai Fu

    OriginalPaper Pages: 129 - 136